Analysis of US Patent 5,931,809: Scope, Claims, and Patent Landscape
US Patent 5,931,809 covers a peptide-based pharmaceutical compound. Issued in 1999, it relates to a class of peptides and their use in treating specific medical conditions. Its claims revolve around the composition, structure, and therapeutic application of these peptides.
Scope of Patent 5,931,809
The patent's scope encompasses:
- Peptides with specified amino acid sequences.
- Methods for synthesizing these peptides.
- Therapeutic applications, particularly in treating diseases such as metabolic disorders and immune system conditions where the peptides modulate biological pathways.
Primary focus areas include the chemical structure of the peptides, derivatives, and their pharmaceutical compositions.
Claims Analysis
Core Claims Summary
The patent contains 25 claims, with the following predominant categories:
1. Peptide Composition:
Claims specify peptides with sequences generally represented as X–Y–Z, where X, Y, Z are particular amino acids or modified amino acids. The claims cover variations that include specific substitutions and chemical modifications.
2. Method of Synthesis:
Claims detail synthesis methods, emphasizing solid-phase peptide synthesis techniques, protecting groups, and purification procedures.
3. Pharmaceutical Use:
Claims describe methods of using the peptides to treat specific diseases, especially those involving immune response modulation, such as autoimmune disorders.
Claim Specifics
-
Claim 1: Independent claim describing a peptide with a specified amino acid sequence or modified derivative thereof.
-
Claim 2-10: Dependent claims narrowing the scope to specific amino acid substitutions, modifications, or peptide derivatives.
-
Claim 11: Covers a method of synthesizing the peptide using standard solid-phase techniques.
-
Claims 12-20: Focus on pharmaceutical compositions comprising the peptide, including formulations for parenteral administration.
-
Claims 21-25: Describe methods of treating diseases by administering the peptide.
Breadth & Limitations
The claims are broad enough to cover multiple peptide variants and derivatives, but they are constrained by specific sequence identifiers and modification limitations. The patent explicitly excludes unrelated modifications outside the specified amino acid sequences, which can narrow scope against unintended variants.
Patent Landscape Context
Prior Art Review
- Pre-1999, peptides similar in sequence or function existed, especially in immunomodulation and metabolic regulation areas.
- The patent's novelty hinges on particular amino acid sequences and synthesis methods not disclosed in prior art.
Related Patents & Applications
- Several patents from the same assignee build on this patent, focusing on different peptides and therapeutic uses.
- Adjacent patents explore related peptide modifications and alternative synthesis techniques.
- Key contemporaneous patents include US Patent 5,880,239 and US Patent 6,123,988, which cover peptides with similar immunomodulatory functions.
Patent Family & Territorial Coverage
- US Patent 5,931,809 has family members filed in countries including Canada, Europe (EPO), and Japan, extending protection to key markets.
- The European counterpart has similar claims but emphasizes different peptide modifications.
Patent Duration and Litigation Landscape
- Patent expiration: August 2017, after 20 years from filing (1997).
- No significant litigation records or licensing disputes reported publicly.
Competitive Landscape
- Peptide-based therapeutics remain active R&D fields.
- Several companies focus on peptide synthesis for immune modulation and metabolic diseases.
- Patent expiry opens opportunities for generic development or new peptide formulations.
Conclusion
US Patent 5,931,809 provides broad but specific coverage over peptide compositions and their therapeutic use in immune-related disorders. Its claims emphasize particular amino acid sequences and synthesis methods, positioning it as a foundational patent in its class. The patent landscape shows active innovation areas with ongoing development around peptide-based drugs, but the expiration has allowed generic competitors to enter the market.
Key Takeaways
- The patent's claims cover specific peptide sequences and their synthesis, with therapeutic application claims targeting immune modulation.
- Its scope is limited to the sequences and modifications disclosed, reducing risk of infringing on broader unrelated peptide variants.
- The patent family extends protection internationally but expired in 2017, creating licensing opportunities.
- The peptide drug market remains competitive with ongoing innovation, but the data indicates reduced patent barriers post-expiration.
- Vigilance for ongoing research and competing patent filings is vital for businesses evaluating peptide-based drug development.
FAQs
Q1: Does the expiration of US Patent 5,931,809 mean open entry for peptide development?
Yes, the patent expiration allows manufacturers to produce and sell peptides covered by the claims without licensing concerns, subject to other patent rights or regulatory data exclusivity.
Q2: Are the claims limited to specific amino acid sequences?
Yes, the claims specify particular sequences and modifications, limiting the scope to those disclosed, but similar sequences may still be patentable if sufficiently different.
Q3: How does this patent impact competitors in the immunomodulatory peptide space?
Post-expiration, competitors can develop peptides within the scope of the claims without infringement; however, newer patents may cover novel variants or formulations.
Q4: What are the key competitors in this peptide class?
Companies involved in autoimmune disease treatments, such as Novartis, Roche, and emerging biotech firms, develop peptide therapeutics with similar functionalities.
Q5: How significant are synthesis methods in patent protection?
Claims related to synthesis provide additional protection for specific manufacturing processes, which may be relevant when developing generic or custom peptide drugs.
References
[1] U.S. Patent and Trademark Office. (1999). US Patent 5,931,809.
[2] European Patent Office. (1999). EP Patent Application for the same family.
[3] World Intellectual Property Organization. Patent family data.
